FDA adds vision loss warning to diabetes drugs - diabetes drugs
The new packaging will alert patients to their risk of developing NAION, which is caused by a lack of blood flowing to the optic nerve.

The US Food and Drug Administration (FDA) announced in November 2026 that it will update packaging requirements for GLP-1-based drugs to include a new warning about a rare side effect that could affect users’ eyes. Researchers have raised concerns that GLP-1s could increase the risk of developing non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can trigger sudden painless decreased vision in one eye, sometimes leading to permanent vision loss.

The FDA made their decision after examining evidence from over 100 clinical trials, which showed that the risk of a person having treatment for obesity getting NAION is 3.8 cases per 100,000 patient years, but this risk jumps to 6.4 per 100,000 patient years if the treatment is a GLP-1-based drug. The new packaging will alert patients to their risk of developing NAION, which is caused by a lack of blood flowing to the optic nerve.

NAION and Vision Loss

Doctors are not sure exactly how NAION happens, but the chances of developing it increase if a person smokes, or has diabetes, kidney disease, high blood pressure, or sleep apnoea. This revision was triggered by the release of a 2024 study in JAMA Ophthalmology, which reported an increase in the number of cases of NAION in people prescribed semaglutide, the active ingredient in Wegovy and Ozempic.

After following up with an epidemiological cohort study, researchers confirmed that semaglutide was linked to a small increase in the number of cases of vision loss. Since then, researchers have realized that every single GLP-1-based medication is linked to a small increase in the risk of NAION. The FDA scientists reviewed all of the clinical trials and animal testing safety data they could find to figure out how much GLP-1 receptor agonists changed a person’s risk of developing NAION.

They discovered that of the 78,217 GLP-1 users and 56,036 patients receiving a control drug, 10 people using GLP-1s developed NAION, while only five people in the control groups developed the condition. This means that only 15 out of 134,000 people were affected, and although the difference in cases between GLP-1 drugs and equivalent non-GLP-1 drugs was statistically significant, it was still a very small risk.

FDA Advice and Next Steps

The FDA advises doctors and patients to keep an eye out for any vision changes, and patients should visit an ophthalmologist if they notice sudden, painless vision loss in one eye, blurred or missing portions of vision, distortion of colours, or reduced central sharpness. The FDA is not suggesting any changes to how doctors routinely prescribe GLP-1-based drugs, as the risk to health posed by untreated Type 2 diabetes and obesity-driven metabolic syndrome is very serious.

In terms of comparable medications, the FDA’s side effect reporting system showed that between 2019 and 2024, amongst people getting treatment for diabetes, there were 30-32 cases of NAION per 100,000 patient years for those using GLP-1-based drugs, 31 cases for those using SGLT-2 inhibitors, and 26 cases for those using dipeptidyl peptidase-4 inhibitors. The affected drugs and brands include Ozempic, Wegovy, Rybelsus, Semaglutide, Victoza, Saxenda, Xultophy, Liraglutide, Trulicity, Dulaglutide, lixisenatide, Mounjaro, Zepbound, Tirzepatide, and Foundayo.

GLP-1-Based Medications and Risk Factors

The risk factors for NAION, such as unmanaged type 2 diabetes, can be caused by various factors, including smoking, diabetes, kidney disease, high blood pressure, or sleep apnoea. For some people, the benefit of using GLP-1s to prevent NAION might be far greater than any risk GLP-1s might add to the baseline.